Corporate Communications
Week ending August 22, 2026
1. This week’s narrative in one paragraph
AI assistants are characterizing ivermectin in a mostly cautious, context-dependent way. They distinguish human products and uses from veterinary products, and oral tablets from topical formulations, while repeatedly warning that ivermectin should not be treated as a COVID-19 therapy. Comparisons with albendazole are described as partly evidence-based but often oversimplified or “marketing-driven”; ivermectin–doxycycline comparisons are more often called “promotional framing” than rigorous evidence comparisons. The tone is generally corrective rather than favorable, with frequent qualifiers and safety disclaimers. Some answers use competitive language such as “best,” “stronger,” or “superior,” but usually to describe or caution against claims seen online, not to promote ivermectin.
2. Anything with public-story potential
-
“AI assistants give inconsistent answers about ivermectin safety.” Across the 10 questions, 17 inconsistency flags show that answers do not consistently mention contraindications, pregnancy/lactation considerations, or infection-risk factors. The clearest public-facing concern is that safety information varies between answers to the same question—not necessarily that every answer is unsafe.
-
“AI assistants disagree on how ivermectin should be discussed for scabies.” Five responses mention contraindication-related issues and two omit them; only one mentions infection risk. A screenshot comparing answers could support a broader story about conflicting AI health guidance involving a recognizable drug.
-
“Ivermectin remains linked online to off-label COVID-era claims.” Seven responses reject COVID-19 treatment use and describe ivermectin–doxycycline comparisons as promotional or advocacy framing. This is more a recurring reputational association than evidence of a new development, but it remains readily understandable to journalists and advocates.
3. Topics with a public-attention history
- Off-label use: Present in 17 tags, especially around scabies and COVID-19. No prior-week comparison is available, so this is a baseline signal, not a demonstrated increase.
- Compounding: Mentioned only once; no visible storyline is developing this week.
- Generic/substitution framing: Generic-product discussion appears 10 times, focused on naming, formulation, and labeling. No competitor mentions or access/pricing narrative is visible.
- Safety concerns: Pregnancy, pediatric use, contraindications, and adverse reactions are prominent themes, though their relevance here is inconsistency as a public trust issue rather than a clinical signal.
4. Trajectory
This is a baseline week: previous-week data are unavailable and the trend history contains only 2026-08-22. We cannot call any topic new, recurring, or building from this dataset alone. Current volume is 70 responses across 10 questions, with 17 inconsistency flags.
5. Recommended actions
- Prepare a short holding statement on conflicting AI health answers, grounded in the principle that product-specific labeling and clinician guidance should take precedence. Loop in Medical Affairs and PV because the same inconsistency has implications in their lanes.
- Prepare talking points on ivermectin’s COVID-19 association, emphasizing that the sampled answers consistently say it is not supported for COVID-19 treatment. This is the most recognizable media narrative.
- Monitor scabies and safety-related prompts, particularly contraindications and pregnancy/pediatric references; no proactive outreach is warranted from this baseline.
- No action on compounding or generic substitution beyond monitoring: signals are limited, with one compounding mention and no competitor or pricing narrative.